372 related articles for article (PubMed ID: 27098830)
1. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
2. Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.
McShane LM; Franklin ZJ; O'Harte FP; Irwin N
Peptides; 2014 Oct; 60():95-101. PubMed ID: 25148830
[TBL] [Abstract][Full Text] [Related]
3. desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.
Irwin N; Franklin ZJ; O'Harte FP
Eur J Pharmacol; 2013 Jun; 709(1-3):43-51. PubMed ID: 23562625
[TBL] [Abstract][Full Text] [Related]
4. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores.
Martin CM; Irwin N; Flatt PR; Gault VA
Biochim Biophys Acta; 2013 Jun; 1830(6):3407-13. PubMed ID: 23518200
[TBL] [Abstract][Full Text] [Related]
5. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice.
O'Harte FP; Franklin ZJ; Irwin N
Diabetes Obes Metab; 2014 Dec; 16(12):1214-22. PubMed ID: 25060150
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists.
O'Harte FP; Franklin ZJ; Rafferty EP; Irwin N
Mol Cell Endocrinol; 2013 Dec; 381(1-2):26-34. PubMed ID: 23891841
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.
Irwin N; McClean PL; Hunter K; Flatt PR
Diabetes Obes Metab; 2009 Jun; 11(6):603-10. PubMed ID: 19515180
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice.
Pathak V; Gault VA; Flatt PR; Irwin N
Mol Cell Endocrinol; 2015 Feb; 401():120-9. PubMed ID: 25449420
[TBL] [Abstract][Full Text] [Related]
9. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
[TBL] [Abstract][Full Text] [Related]
11. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
12. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
13. An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice.
Hasib A; Ng MT; Gault VA; Khan D; Parthsarathy V; Flatt PR; Irwin N
Diabetologia; 2017 Mar; 60(3):541-552. PubMed ID: 28004148
[TBL] [Abstract][Full Text] [Related]
14. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
[TBL] [Abstract][Full Text] [Related]
15. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Diabetes Obes Metab; 2016 Oct; 18(10):1013-24. PubMed ID: 27357054
[TBL] [Abstract][Full Text] [Related]
16. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
[TBL] [Abstract][Full Text] [Related]
18. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
McClean PL; Irwin N; Cassidy RS; Holst JJ; Gault VA; Flatt PR
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1746-55. PubMed ID: 17848629
[TBL] [Abstract][Full Text] [Related]
19. Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic Glu
Sarnobat D; Moffett RC; Gault VA; Tanday N; Reimann F; Gribble FM; Flatt PR; Irwin N
Peptides; 2020 Mar; 125():170205. PubMed ID: 31738969
[TBL] [Abstract][Full Text] [Related]
20. Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.
O'Harte FP; Hunter K; Gault VA; Irwin N; Green BD; Greer B; Harriott P; Bailey CJ; Flatt PR
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1674-82. PubMed ID: 17299087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
